Long-term clinical outcomes of prophylaxis with an rFVIIIFc or rFIXFc in adults aged ≥50 years with hemophilia A or B

Blood Adv. 2024 Sep 24;8(18):4751-4755. doi: 10.1182/bloodadvances.2023012462.

Authors

Doris Quon¹, Shannon Jackson², María Teresa Alvarez-Román³, Umer Khan⁴, Sandra Casiano⁴, Margaret V Ragni⁵, Savita Rangarajan⁶

Affiliations

¹ Orthopaedic Hemophilia Treatment Center, Luskin Orthopaedic Institute for Children, Los Angeles, CA.
² Providence Health Care, St. Paul's Hospital, Vancouver, BC, Canada.
³ Department of Hematology, University Hospital La Paz, Madrid, Spain.
⁴ Sanofi, Cambridge, MA.
⁵ Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA.
⁶ Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Factor VIII* / therapeutic use
Female
Hemophilia A* / drug therapy
Hemophilia B* / drug therapy
Humans
Immunoglobulin Fc Fragments / therapeutic use
Male
Middle Aged
Recombinant Fusion Proteins / therapeutic use
Treatment Outcome

Substances

Factor VIII
Recombinant Fusion Proteins
Immunoglobulin Fc Fragments
factor VIII-Fc fusion protein